Literature DB >> 22160748

Preconditioning with a novel metallopharmaceutical NO donor in anesthetized rats subjected to brain ischemia/reperfusion.

Marcio Wilker Soares Campelo1, Reinaldo Barreto Oriá, Luiz Gonzaga de França Lopes, Gerly Anne de Castro Brito, Armenio Aguiar dos Santos, Raquel Cavalcante de Vasconcelos, Francisco Ordelei Nascimento da Silva, Beatrice Nuto Nobrega, Moisés Tolentino Bento-Silva, Paulo Roberto Leitão de Vasconcelos.   

Abstract

Rut-bpy is a novel nitrosyl-ruthenium complex releasing NO into the vascular system. We evaluated the effect of Rut-bpy (100 mg/kg) on a rat model of brain stroke. Forty rats were assigned to four groups (Saline solution [SS], Rut-bpy, SS+ischemia-reperfusion [SS+I/R] and Rut-bpy+ischemia-reperfusion [Rut-bpy+I/R]) with their mean arterial pressure (MAP) continuously monitored. The groups were submitted (SS+I/R and Rut-bpy+I/R) or not (SS and Rut-bpy) to incomplete global brain ischemia by occlusion of the common bilateral carotid arteries during 30 min followed by reperfusion for further 60 min. Thirty minutes before ischemia, rats were treated pairwise by intraperitoneal injection of saline solution or Rut-bpy. At the end of experiments, brain was removed for triphenyltetrazolium chloride staining in order to quantify the total ischemic area. In a subset of rats, hippocampus was obtained for histopathology scoring, nitrate and nitrite measurements, immunostaining and western blotting of the nuclear factor- κB (NF-κB). Rut-bpy pre-treatment decreased MAP variations during the transition from brain ischemia to reperfusion and decreased the fractional injury area. Rut-bpy pre-treatment reduced NF-κB hippocampal immunostaining and protein expression with improved histopathology scoring as compared to the untreated operated control. In conclusion, Rut-bpy improved the total brain infarction area and hippocampal neuronal viability in part by inhibiting NF-κB signaling and helped to stabilize the blood pressure during the transition from ischemia to reperfusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160748     DOI: 10.1007/s11064-011-0669-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  56 in total

1.  Recovery of brain function during induced cerebral hypoperfusion.

Authors:  R S Marshall; R M Lazar; J Pile-Spellman; W L Young; D H Duong; S Joshi; N Ostapkovich
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

Review 2.  The potential of nitric oxide therapeutics in stroke.

Authors:  M R Willmot; P M W Bath
Journal:  Expert Opin Investig Drugs       Date:  2003-03       Impact factor: 6.206

Review 3.  Exciting, radical, suicidal: how brain cells die after stroke.

Authors:  Eng H Lo; Michael A Moskowitz; Thomas P Jacobs
Journal:  Stroke       Date:  2005-01-06       Impact factor: 7.914

4.  Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury.

Authors:  R M Pluta; R Rak; D A Wink; J J Woodward; A Khaldi; E H Oldfield; J C Watson
Journal:  Neurosurgery       Date:  2001-04       Impact factor: 4.654

5.  How to repair an ischemic brain injury? Value of experimental models in search of answers.

Authors:  R Prieto-Arribas; J M Pascual-Garvi; F González-Llanos; J M Roda
Journal:  Neurologia       Date:  2011-03       Impact factor: 3.109

6.  Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes.

Authors:  Jack C de la Torre; Gjumrakch Aliev
Journal:  J Cereb Blood Flow Metab       Date:  2005-06       Impact factor: 6.200

7.  A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats.

Authors:  R Zhang; L Zhang; Z Zhang; Y Wang; M Lu; M Lapointe; M Chopp
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

8.  Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases.

Authors:  S P Fricker; E Slade; N A Powell; O J Vaughan; G R Henderson; B A Murrer; I L Megson; S K Bisland; F W Flitney
Journal:  Br J Pharmacol       Date:  1997-12       Impact factor: 8.739

9.  Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke.

Authors:  Mushfiquddin Khan; Manu Jatana; Chinnasamy Elango; Ajaib Singh Paintlia; Avtar K Singh; Inderjit Singh
Journal:  Nitric Oxide       Date:  2006-03-09       Impact factor: 4.427

10.  Stimulus-dependent activation of NF-kappaB specifies apoptosis or neuroprotection in cerebellar granule cells.

Authors:  Barbara Kaltschmidt; Michael Heinrich; Christian Kaltschmidt
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 4.103

View more
  8 in total

1.  The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.

Authors:  Pedro Cabrales; Scott Caroen; Arnold Oronsky; Corey Carter; Jane Trepel; Thomas Summers; Tony Reid; Neil Oronsky; Michelle Lybeck; Bryan Oronsky
Journal:  Expert Rev Hematol       Date:  2017-05-22       Impact factor: 2.929

2.  A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice.

Authors:  Dmitriy N Atochin; Igor A Schepetkin; Andrei I Khlebnikov; Victor I Seledtsov; Helen Swanson; Mark T Quinn; Paul L Huang
Journal:  Neurosci Lett       Date:  2016-02-26       Impact factor: 3.046

Review 3.  Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy.

Authors:  Shaunik Sharma; Sreekanth Puttachary; Thimmasettappa Thippeswamy
Journal:  J Neurosci Res       Date:  2017-12-12       Impact factor: 4.164

4.  The ruthenium nitric oxide donor, [Ru(HEDTA)NO], inhibits acute nociception in mice by modulating oxidative stress, cytokine production and activating the cGMP/PKG/ATP-sensitive potassium channel signaling pathway.

Authors:  Larissa Staurengo-Ferrari; Sandra S Mizokami; Victor Fattori; Jean J Silva; Patrícia G Zanichelli; Sandra R Georgetti; Marcela M Baracat; Luiz G da França; Wander R Pavanelli; Rubia Casagrande; Waldiceu A Verri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-13       Impact factor: 3.000

5.  The reduction of EPSC amplitude in CA1 pyramidal neurons by the peroxynitrite donor SIN-1 requires Ca2+ influx via postsynaptic non-L-type voltage gated calcium channels.

Authors:  Liu Zhaowei; Xie Yongling; Yang Jiajia; Yang Zhuo
Journal:  Neurochem Res       Date:  2013-12-28       Impact factor: 3.996

6.  A divergent mode of activation of a nitrosyl iron complex with unusual antiangiogenic activity.

Authors:  Edinilton Muniz Carvalho; Lisa A Ridnour; Florêncio Sousa Gouveia Júnior; Pedro Henrique Bezerra Cabral; Nilberto Robson Falcão do Nascimento; David A Wink; Douglas W Franco; Mayara Jane Campos de Medeiros; Daniel de Lima Pontes; Elisane Longhinotti; Tércio de Freitas Paulo; Vania Bernardes-Génisson; Remi Chauvin; Eduardo Henrique Silva Sousa; Luiz Gonzaga de França Lopes
Journal:  J Inorg Biochem       Date:  2020-06-20       Impact factor: 4.155

7.  New metallophamaceutic reduced renal injury induced by non-steroidal anti-inflammatory.

Authors:  Clóvis Ney Pinheiro Macêdo; Francisco Evanilso Silva Braga; Ana Paula Bomfim Soares Campelo; Gabriel Maia Diniz; Luiz Gonzaga de França Lopes; Marcos Kubrusly; Marcio Wilker Soares Campelo
Journal:  Acta Cir Bras       Date:  2020-02-03       Impact factor: 1.388

8.  Thiol-Activated HNO Release from a Ruthenium Antiangiogenesis Complex and HIF-1α Inhibition for Cancer Therapy.

Authors:  Eduardo Henrique Silva Sousa; Lisa A Ridnour; Florêncio S Gouveia; Carlos Daniel Silva da Silva; David A Wink; Luiz Gonzaga de França Lopes; Peter J Sadler
Journal:  ACS Chem Biol       Date:  2016-05-31       Impact factor: 5.100

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.